Drug

Warfarin

Regulatory activity · MHRA

Emerging researchLate-stage developmentRising momentum

Also known as 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumadin, Jantoven, Zoocoumarin+2 more

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumadin, Jantoven, Zoocoumarin, Warfarina, Warfarin Sodium.

RxNorm11289 ChEMBLCHEMBL1464 ATCB01AA03UNII5Q7ZVV76EI

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Vitamin K Reversal of INR for Perioperative Management of Warfarin: : A Pilot Study to Assess Feasibility

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Prospective, Multicenter, Randomized Controlled Trial Evaluating the Safety and Efficacy of Different Antithrombotic Therapy Strategies in Patients With Severe Aortic Regurgitation Undergoing Transcatheter Aortic Valve Replacement

Clinical trial2026-07-01Results expected Q3 2029 · ClinicalTrials.gov

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

Clinical trial2026-06-24Results expected Q3 2027 · ClinicalTrials.gov

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Dysfunction With Multimodality Imaging and Its TrEatment With Anticoagulation

Clinical trial2026-06-16Results expected Q4 2028 · ClinicalTrials.gov

The Danish Warfarin-Dialysis Study: Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis - A Nationwide Parallel-group Open Randomized Clinical Trial

Clinical trial2026-05-19Results expected Q1 2027 · ClinicalTrials.gov

Drug Safety Update: Warfarin: be alert to the risk of drug interactions with tramadol

Regulatory2024-06-20MHRA

Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.

Research2024-01-25Drug safety

Drug Safety Update: Warfarin: reports of calciphylaxis

Regulatory2016-07-18MHRA

Drug Safety Update: Warfarin: product information to be amended to give clearer, up-to-date advice

Regulatory2014-12-11MHRA

Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

Research2014-11-01JAMA

Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.

Research2014-04-07Circulation journal : official journal of the Japanese Circulation Society

Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial.

Research2014-01-30Hypertension research : official journal of the Japanese Society of Hypertension

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Warfarin

Aliases & brands

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarinCoumadinJantovenZoocoumarinWarfarinaWarfarin Sodium

RxNorm CUI

11289

ChEMBL ID

CHEMBL1464

ATC codes

B01AA03

UNII

5Q7ZVV76EI

Regulatory jurisdictions

mhra

Regulatory timeline

3 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 3 events

2024-06-20Safety communicationSafety

Drug Safety Update: Warfarin: be alert to the risk of drug interactions with tramadol

Evidence ↗

2016-07-18Safety communicationSafety

Drug Safety Update: Warfarin: reports of calciphylaxis

Evidence ↗

2014-12-11Safety communicationSafety

Drug Safety Update: Warfarin: product information to be amended to give clearer, up-to-date advice

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

188 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

188

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

107

Late-stage (III+)

123

Completed

Discontinued

PHASE DISTRIBUTIONn = 188

Early Phase 12Phase 156Phase 1 / 21Phase 222Phase 2 / 34Phase 346Phase 436Phase N / A21

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)

RecruitingPH IVSeoul National University Hospitaln=2002029

RandomizEd compariSOn of Apixaban Versus Warfarin in Patients With Left VEntricular Thrombus After Acute Myocardial Infarction (RESOLVE-AMI)

RecruitingPH IVKarolinska Institutetn=2122028

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair: a Prospective, Non-inferiority, Randomized Controlled Clinical Trial Protocol

RecruitingPH IVGuangdong Provincial People's Hospitaln=3842027

Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial

Active, not recruitingPH IVThe University of Hong Kongn=3702027

Delayed ARIES: Aspirin and Hemocompatibility Events in Advanced Heart Failure Patients Chronically Supported With a Left Ventricular Assist Device

RecruitingPH IVColumbia Universityn=1282027

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression

CompletedPH IINational Cancer Institute (NCI)n=342026

To Determine the Safety and Efficacy of Oral Rivaroxaban and Standard Anticoagulant in the Treatment of Cerebrosinovenous Thrombosis in Children

CompletedN/AMuhammad Aamir Latifn=752025

Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open-label, Phase IIb, Non-inferiority Proof of Principle Trial.

CompletedPH IIUniversity College, Londonn=432025

A Single Center, Open-label, Fixed Sequence Trial, Investigating the Influence of BGM0504 Injection on Gastric Emptying and Pharmacokinetics of Metformin and Warfarin in Overweight or Obese Participants

CompletedPH IBrightGene Bio-Medical Technology Co., Ltd.n=282025

Dose Prediction for Statins and Anticoagulant Medications in Cirrhotic Patients Using Simcyp Program: Applications in Clinical Practice

CompletedPH IVKafrelsheikh Universityn=212025

A Phase 1, Open-label, Drug-Drug Interaction Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple CYP450 Substrates in Patients With Moderate to Severe Atopic Dermatitis

CompletedPH IAmgenn=212025

Research activity

13 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20022024

Most influential

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

The New England journal of medicine · 2003 · 1,599 cites

Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

JAMA · 2002 · 1,354 cites

Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

JAMA · 2014 · 679 cites

Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.

Circulation journal : official journal of the Japanese Circulation Society · 2012 · 489 cites

Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.

Circulation journal : official journal of the Japanese Circulation Society · 2013 · 55 cites

Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.

Circulation journal : official journal of the Japanese Circulation Society · 2014 · 50 cites

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Digoxin

Studied across 4 of the same disease areas as Warfarin in the shared literature.

4 shared diseases2 shared papers

Acenocoumarol

Studied across 5 of the same disease areas as Warfarin in the shared literature.

5 shared diseases1 shared paper

Dalteparin

Studied across 5 of the same disease areas as Warfarin in the shared literature.

5 shared diseases1 shared paper

Amiodarone

Studied across 4 of the same disease areas as Warfarin in the shared literature.

4 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.